SOLTF
Price
$6.52
Change
+$0.36 (+5.84%)
Updated
Jan 6 closing price
Capitalization
505.31M
SRBCF
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Feb 21 closing price
Capitalization
11.87M
Ad is loading...

SOLTF vs SRBCF

Header iconSOLTF vs SRBCF Comparison
Open Charts SOLTF vs SRBCFBanner chart's image
Nxera Pharma
Price$6.52
Change+$0.36 (+5.84%)
Volume$200
Capitalization505.31M
Sirona Biochem
Price$0.05
Change-$0.00 (-0.00%)
Volume$10K
Capitalization11.87M
SOLTF vs SRBCF Comparison Chart
Loading...
View a ticker or compare two or three
VS
SOLTF vs. SRBCF commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SOLTF is a Hold and SRBCF is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (SOLTF: $6.52 vs. SRBCF: $0.05)
Brand notoriety: SOLTF and SRBCF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SOLTF: 122% vs. SRBCF: 12%
Market capitalization -- SOLTF: $505.31M vs. SRBCF: $11.87M
SOLTF [@Biotechnology] is valued at $505.31M. SRBCF’s [@Biotechnology] market capitalization is $11.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SOLTF’s FA Score shows that 0 FA rating(s) are green whileSRBCF’s FA Score has 0 green FA rating(s).

  • SOLTF’s FA Score: 0 green, 5 red.
  • SRBCF’s FA Score: 0 green, 5 red.
According to our system of comparison, SRBCF is a better buy in the long-term than SOLTF.

Price Growth

SOLTF (@Biotechnology) experienced а 0.00% price change this week, while SRBCF (@Biotechnology) price change was -0.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
SOLTF($505M) has a higher market cap than SRBCF($11.9M). SOLTF YTD gains are higher at: 5.887 vs. SRBCF (0.879). SRBCF has higher annual earnings (EBITDA): -2.03M vs. SOLTF (-3.81B). SOLTF has more cash in the bank: 51B vs. SRBCF (27.3K). SRBCF has less debt than SOLTF: SRBCF (2.73M) vs SOLTF (71.1B). SOLTF has higher revenues than SRBCF: SOLTF (23.3B) vs SRBCF (-12.09K).
SOLTFSRBCFSOLTF / SRBCF
Capitalization505M11.9M4,244%
EBITDA-3.81B-2.03M187,477%
Gain YTD5.8870.879670%
P/E RatioN/AN/A-
Revenue23.3B-12.09K-192,705,318%
Total Cash51B27.3K186,813,187%
Total Debt71.1B2.73M2,602,489%
FUNDAMENTALS RATINGS
SOLTF vs SRBCF: Fundamental Ratings
SOLTF
SRBCF
OUTLOOK RATING
1..100
4488
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
93100
PRICE GROWTH RATING
1..100
8157
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SOLTF's Valuation (86) in the null industry is in the same range as SRBCF (95). This means that SOLTF’s stock grew similarly to SRBCF’s over the last 12 months.

SOLTF's Profit vs Risk Rating (100) in the null industry is in the same range as SRBCF (100). This means that SOLTF’s stock grew similarly to SRBCF’s over the last 12 months.

SOLTF's SMR Rating (93) in the null industry is in the same range as SRBCF (100). This means that SOLTF’s stock grew similarly to SRBCF’s over the last 12 months.

SRBCF's Price Growth Rating (57) in the null industry is in the same range as SOLTF (81). This means that SRBCF’s stock grew similarly to SOLTF’s over the last 12 months.

SRBCF's P/E Growth Rating (100) in the null industry is in the same range as SOLTF (100). This means that SRBCF’s stock grew similarly to SOLTF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PHAT5.670.13
+2.35%
Phathom Pharmaceuticals
LBTYK11.910.03
+0.25%
Liberty Global Ltd
ACHL1.38-0.01
-0.72%
Achilles Therapeutics plc
BTI37.85-0.70
-1.82%
British American Tobacco plc
CUBI53.27-2.37
-4.26%
Customers Bancorp

SOLTF and

Correlation & Price change

A.I.dvisor indicates that over the last year, SOLTF has been loosely correlated with BIESF. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SOLTF jumps, then BIESF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SOLTF
1D Price
Change %
SOLTF100%
N/A
BIESF - SOLTF
35%
Loosely correlated
N/A
BSFAF - SOLTF
29%
Poorly correlated
N/A
SPHRF - SOLTF
23%
Poorly correlated
N/A
SLNCF - SOLTF
9%
Poorly correlated
N/A
SRBCF - SOLTF
6%
Poorly correlated
N/A
More

SRBCF and

Correlation & Price change

A.I.dvisor tells us that SRBCF and BCLI have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SRBCF and BCLI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRBCF
1D Price
Change %
SRBCF100%
N/A
BCLI - SRBCF
25%
Poorly correlated
-3.89%
PRTG - SRBCF
21%
Poorly correlated
-2.56%
TRRI - SRBCF
12%
Poorly correlated
N/A
VBIZF - SRBCF
12%
Poorly correlated
N/A
SBMFF - SRBCF
8%
Poorly correlated
N/A
More